Latest News and Press Releases

SAN DIEGO, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Histogen Inc. (Nasdaq: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class therapeutics that ignite the body’s...

Topline Data for HST-001 Phase 1b/2a Trial for Androgenic Alopecia in Men on Track for 4Q20 Received $2M Grant Award from the Department of Defense for Clinical Advancement of HST-003 for Cartilage...

SAN DIEGO, Oct. 28, 2020 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite...

Histogen Receives IND Approval from FDA to Initiate a Phase 1 Study of Emricasan in Mild-COVID-19 Patients to Assess Safety and Tolerability Amerimmune to Lead Development Efforts of Emricasan in a...

SAN DIEGO, Oct. 19, 2020 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite...

SAN DIEGO, Oct. 05, 2020 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite...

HST-002 Designated as Drug-Biologic-Device Combination Product HST-001 1b/2a Trial for Androgenic Alopecia in Men on Track for Top Line Data Results in 4Q20 HST-003 IND Submission for Regeneration...

Investigational New Drug (IND) Filing Expected in the Fourth Quarter of 2020 SAN DIEGO, Sept. 16, 2020 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company...

SAN DIEGO, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO),  a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite...

SAN DIEGO, Sept. 01, 2020 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite...